IDEXX Laboratories, Inc. (NASDAQ:IDXX) Receives Average Rating of “Moderate Buy” from Analysts

Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) have been assigned a consensus rating of “Moderate Buy” from the ten ratings firms that are presently covering the firm, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $747.00.

Several brokerages recently commented on IDXX. UBS Group boosted their price target on IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a research note on Wednesday, August 5th. Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Citigroup increased their price objective on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. Barclays cut their price objective on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a report on Tuesday, August 11th. Finally, Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, August 27th.

IDEXX Laboratories Trading Up 0.6%

Shares of NASDAQ:IDXX opened at $513.62 on Thursday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17. The stock’s 50-day moving average is $552.45 and its 200-day moving average is $563.00. The company has a market cap of $40.46 billion, a P/E ratio of 36.12, a P/E/G ratio of 2.73 and a beta of 1.54. IDEXX Laboratories has a 52-week low of $500.61 and a 52-week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.94 by $0.33. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The business had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.20 billion. During the same quarter last year, the company posted $3.50 earnings per share. IDEXX Laboratories’s quarterly revenue was up 9.7% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Equities research analysts predict that IDEXX Laboratories will post 14.81 earnings per share for the current year.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, Director Lawrence D. Kingsley sold 2,203 shares of the business’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $532.08, for a total value of $1,172,172.24. Following the transaction, the director directly owned 9,568 shares in the company, valued at $5,090,941.44. The trade was a 18.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.79% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. National Pension Service boosted its holdings in shares of IDEXX Laboratories by 5.6% in the 2nd quarter. National Pension Service now owns 129,305 shares of the company’s stock worth $68,071,000 after acquiring an additional 6,885 shares in the last quarter. Engineers Gate Manager LP grew its position in IDEXX Laboratories by 162.6% during the 2nd quarter. Engineers Gate Manager LP now owns 5,186 shares of the company’s stock worth $2,730,000 after acquiring an additional 3,211 shares during the last quarter. IFP Advisors Inc increased its holdings in IDEXX Laboratories by 9.8% during the 2nd quarter. IFP Advisors Inc now owns 585 shares of the company’s stock valued at $308,000 after purchasing an additional 52 shares in the last quarter. Sterling Investment Advisors Ltd. increased its holdings in IDEXX Laboratories by 9.1% during the 2nd quarter. Sterling Investment Advisors Ltd. now owns 1,200 shares of the company’s stock valued at $632,000 after purchasing an additional 100 shares in the last quarter. Finally, Arizona State Retirement System raised its position in IDEXX Laboratories by 4.9% in the 2nd quarter. Arizona State Retirement System now owns 22,772 shares of the company’s stock valued at $11,988,000 after purchasing an additional 1,074 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops and provides diagnostic, information technology and veterinary practice-management products and services. The company primarily serves the companion animal, livestock and poultry, and water testing markets, helping customers detect, monitor and manage disease.

Its companion animal business includes in-house laboratory analyzers and consumables, reference laboratory services, diagnostic tests, veterinary software, digital imaging and related practice-management solutions.